Metagenomi Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.79 Intrinsic Value $1.52median of 2 methodsbased on filings through 31 Mar 2026 Market Price $1.10Price as of 1 Oct 2026 UndervaluedIntrinsic value is 39% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $41.7M Enterprise Value $43.4M Shares Outstanding 37.8M diluted Next Earnings Date10 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Metagenomi Therapeutics, Inc. (NASDAQ: MGX) is a preclinical-stage gene editing company that has undergone a significant strategic pivot to preserve capital. Following a 25% workforce reduction and a leadership transition appointing Dr. Jian Irish as CEO, the company is hyper-focused on its lead hemophilia A program, MGX-001, and its cardiometabolic collaboration with Ionis Pharmaceuticals. While preclinical data in non-human primates has demonstrated curative potential, the company remains pre-revenue and highly speculative. The current cash runway extends through Q4 2027, providing a buffer to reach key clinical inflection points, but near-term stock performance will be highly sensitive to binary regulatory milestones, specifically the planned IND submission for MGX-001 in Q4 2026. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$5.00 Mean target$7.00 High · most bullish analyst$9.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $5.0020% The bear case is triggered by regulatory delays in the IND submission of MGX-001, safety concerns in preclinical models, or a faster-than-expected cash burn. If the clinical entry is delayed past 2027, the company will face a severe capital crunch, forcing highly dilutive equity raises at depressed valuations or the suspension of key pipeline assets. Base CaseCentral scenario $9.0055% The base case assumes Metagenomi successfully submits the IND for MGX-001 in Q4 2026 and maintains its disciplined spending, keeping its cash runway intact through late 2027. The stock is expected to trade in a range reflecting its cash value and preclinical status, with moderate appreciation as it approaches clinical-stage transition in 2027. Bull CaseUpside scenario $9.0025% The bull case relies on the seamless execution of the MGX-001 program. If the IND is cleared by the FDA in Q4 2026 and clinical trials begin successfully in 2027, demonstrating the same curative factor VIII activity in humans as seen in non-human primates, Metagenomi's proprietary metagenomics platform will be validated. This would likely trigger significant upward revaluation, attract new high-profile biopharma partnerships, and secure non-dilutive funding. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |